Fusidic acid and sodium fusidate (fusidin) are antibiotics with low toxicity and powerful immunomodulatory activities in vitro and in vivo. In this study we have evaluated the effect of fusidin on the development of dinitrobenzenesulfonic acid (DNB)-induced colitis in rats that serves as a preclinical model of human inflammatory bowel disease (IBD). The data show that when administered orally at the dose of 80 (but not 40) mg/kg body wt under a "therapeutic" regimen soon after DNB application, fusidin significantly ameliorates clinical, histological, and seroimmunological signs of disease. These entailed a significant reduction in body weight loss, smaller increase in colon weights, milder macroscopic damage, and lower histological scores. In addition, when sacrificed at the end of the study, fusidin-treated rats had significantly lower blood levels of tumor necrosis factor α and interferon-γ compared with untreated controls. The present findings concur with the beneficial actions of fusidin in a pilot study conducted in patients with Crohn's disease and warrant controlled studies in humans with IBD. © 2003 Elsevier Inc. All rights reserved.

Di Marco, R., Mangano, K., Quattrocchi, C., Musumeci, R., Speciale, A., Papaccio, G., et al. (2003). Curative effects of sodium fusidate on the development of dinitrobenzenesulfonic acid-induced colitis in rats. CLINICAL IMMUNOLOGY, 109(3), 266-271.

Curative effects of sodium fusidate on the development of dinitrobenzenesulfonic acid-induced colitis in rats

MUSUMECI, ROSARIO;
2003

Abstract

Fusidic acid and sodium fusidate (fusidin) are antibiotics with low toxicity and powerful immunomodulatory activities in vitro and in vivo. In this study we have evaluated the effect of fusidin on the development of dinitrobenzenesulfonic acid (DNB)-induced colitis in rats that serves as a preclinical model of human inflammatory bowel disease (IBD). The data show that when administered orally at the dose of 80 (but not 40) mg/kg body wt under a "therapeutic" regimen soon after DNB application, fusidin significantly ameliorates clinical, histological, and seroimmunological signs of disease. These entailed a significant reduction in body weight loss, smaller increase in colon weights, milder macroscopic damage, and lower histological scores. In addition, when sacrificed at the end of the study, fusidin-treated rats had significantly lower blood levels of tumor necrosis factor α and interferon-γ compared with untreated controls. The present findings concur with the beneficial actions of fusidin in a pilot study conducted in patients with Crohn's disease and warrant controlled studies in humans with IBD. © 2003 Elsevier Inc. All rights reserved.
Articolo in rivista - Articolo scientifico
sodium fusidate, colitis
English
2003
109
3
266
271
reserved
Di Marco, R., Mangano, K., Quattrocchi, C., Musumeci, R., Speciale, A., Papaccio, G., et al. (2003). Curative effects of sodium fusidate on the development of dinitrobenzenesulfonic acid-induced colitis in rats. CLINICAL IMMUNOLOGY, 109(3), 266-271.
File in questo prodotto:
File Dimensione Formato  
Curative effects of sodium fusidate on the development of dinitrobenzenesulfonic acid-induced colitis in rats Clin Immun 2003.pdf

Solo gestori archivio

Tipologia di allegato: Other attachments
Dimensione 374.97 kB
Formato Adobe PDF
374.97 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/5320
Citazioni
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 5
Social impact